跳转至内容
Merck

Y0001067

氨氯地平

European Pharmacopoeia (EP) Reference Standard

别名:

苯磺酸氨氯地平, 2-[(2-氨基乙氧基)-甲基]-4-(2-氯苯基)-1,4-二氢-6-甲基-3,5-吡啶二甲酸 3-乙基 5-甲酯苯磺酸酯, 活络喜(抗高血压药)

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C20H25ClN2O5 · C6H5SO3H
分子量:
567.05
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

amlodipine

製造商/商標名

EDQM

應用

pharmaceutical (small molecule)

格式

neat

儲存溫度

2-8°C

SMILES 字串

OS(=O)(=O)c1ccccc1.CCOC(=O)C2=C(COCCN)NC(C)=C(C2c3ccccc3Cl)C(=O)OC

InChI

1S/C20H25ClN2O5.C6H6O3S/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21;7-10(8,9)6-4-2-1-3-5-6/h5-8,17,23H,4,9-11,22H2,1-3H3;1-5H,(H,7,8,9)

InChI 密鑰

ZPBWCRDSRKPIDG-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Amlodipine for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

生化/生理作用

氨氯地平是一种 L 型钙通道阻滞剂。氨氯地平属于一类心血管药物,作用于 Ca V 1 或 L 型的电压门控钙通道。氨氯地平还具有降压和抗心绞痛作用。其活性主要存在于 (-)-异构体中。氨氯地平抑制人表皮样癌细胞 A431 的生长,对雄性大鼠有抗生殖作用。

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

象形圖

Exclamation mark

訊號詞

Warning

危險聲明

危險分類

Acute Tox. 4 Oral

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


Choose from one of the most recent versions:

分析证书(COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Juliano Lara Fernandes et al.
The American journal of medicine, 126(9), 834-837 (2013-07-09)
Iron chelation therapy in patients with thalassemia major may not prevent iron overload in all organs, especially those in which iron enters cells through specific calcium channels. We designed a controlled pilot study to assess the potential of the calcium
Giuseppe Derosa et al.
Journal of the American Society of Hypertension : JASH, 7(1), 32-39 (2013-01-17)
The purpose of this study was to evaluate a fixed olmesartan/amlodipine combination on blood pressure control, lipid profile, insulin sensitivity, and some inflammatory markers compared with single-drug monotherapy. A total of 276 hypertensive patients were randomly assigned to olmesartan 20
László Bajnok
Orvosi hetilap, 154(7), 243-247 (2013-02-12)
From the evaluated ONTARGET, ALTITUDE, ACCOMPLISH, ROADMAP, and ACCORD-BP studies a conclusion can be drawn that though microalbuminuria/proteinuria is a strong epidemiological biomarker, in interventional studies it is not necessarily a reliable surrogate endpoint as actual renal function may change
Christopher J Cooper et al.
The New England journal of medicine, 370(1), 13-22 (2013-11-20)
Atherosclerotic renal-artery stenosis is a common problem in the elderly. Despite two randomized trials that did not show a benefit of renal-artery stenting with respect to kidney function, the usefulness of stenting for the prevention of major adverse renal and
Mehmet Gumustas et al.
Journal of AOAC International, 96(4), 751-757 (2013-09-05)
A stability-indicating RP-LC assay method was developed for the simultaneous determination of the cardiovascular drugs amlodipine and perindopril in the presence of degradation products generated from forced decomposition studies. The developed method is applicable for the determination of related substances

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门